Antifungal Susceptibility Patterns, In Vitro Production of Virulence Factors, and Evaluation of Diagnostic Modalities for the Speciation of Pathogenic Candida from Blood Stream Infections and Vulvovaginal Candidiasis

Table 3

Antifungal susceptibility patterns of Candida spp.

Antifungal agent	Fluconazole			Flucytosine*			Voriconazole			Amphotericin-B*			Caspofungin
Susceptibility pattern 𝑛 (%)	S	I	R	S	I	R	S	I	R	S	I	R	S	I	R
CLSI**; breakpoints; (μg/mL)	≤2	4	≥8	≤4	8–16	≥32	≤0.12	0.25–0.5	≥1	≤4	8–16	≥32	≤0.25	0.5	≥1
C. albicans; (𝑁=41)	39 (95)	2 (5)	—	41 (100)	—	—	40 (97.5)	1 (2.5)	—	41 (100)	—	—	40 (97.5)	—	1 (2.5)
C. tropicalis; (𝑁=29)	29 (100)	—	—	29 (100)	—	—	23 (79)	6 (21)	—	29 (100)	—	—	28 (96.5)	—	1 (3.5)
C. parapsilosis; (𝑁=19)	19 (100)	—	—	19 (100)	—	—	12 (64)	6 (31)	1 (5)	19 (100)	—	—	19 (100)	—	—
C. glabrata *; (𝑁=13)	13 (100)	—	—	13 (100)	—	—	12 (92)	1 (8)	—	13 (100)	—	—	13 (100)	—	—
C. krusei; (𝑁=3)	—	—	R*	3 (100)	—	—	3 (100)	—	—	3 (100)	—	—	3 (100)	—	—

S: sensitive; I: intermediate; R: resistant.
Susceptibility patterns presented as frequency (%).
**MIC breakpoints of YST006 AFT cards used in Vitek 2 Compact system. Interpretation based on CLSI M27-S4 Volume 32.
*MIC breakpoints for Candida spp.
R* Intrinsic resistance.